5 Key Takeaways

• 1

  Topical drops remain a common first-line treatment for glaucoma, with 74% of ASCRS members using them as initial therapy.

• 2

  Dr. Bacharach advocates for a minimal instillation drop strategy (MIDS) to limit medications while enhancing their targeted use.

• 3

  Preservatives in drops can negatively impact ocular surface health, and many medications are now available in preservative-free formulations.

• 4

  Adherence to glaucoma medication regimens is crucial, as missed doses correlate with worse visual outcomes.

• 5

  Future research may refine the strategic use of drops in conjunction with procedural interventions to optimize glaucoma treatment.